Kiniksa Pharmaceuticals International Plc logo

Kiniksa Pharmaceuticals International Plc Share Price Today

(NASDAQ: KNSA)

Kiniksa Pharmaceuticals International Plc share price is $18.74 & ₹1,632.16 as on 5 Feb 2025, 2.30 'hrs' IST

$18.74

-0.14

(-0.74%)

Market is closed - opens 8 PM, 05 Feb 2025

View live Kiniksa Pharmaceuticals International Plc share price in Dollar and Rupees. Guide to invest in Kiniksa Pharmaceuticals International Plc stock from India, including Indian investor sentiment. Get details on Indian mutual funds investing in Kiniksa Pharmaceuticals International Plc, along with analyst recommendations, forecasts, and comprehensive financials.

Kiniksa Pharmaceuticals International Plc share price movements

  • Today's Low: $18.74
    Today's High: $19.19

    Day's Volatility :2.34%

  • 52 Weeks Low: $16.56
    52 Weeks High: $28.15

    52 Weeks Volatility :41.17%

Kiniksa Pharmaceuticals International Plc (KNSA) Returns

PeriodKiniksa Pharmaceuticals International PlcSector (Health Care)Index (Russel 2000)
3 Months
-18.02%
0.5%
0.0%
6 Months
-21.37%
-2.3%
0.0%
1 Year
2.11%
3.8%
0.0%
3 Years
74.81%
11.4%
-11.7%

Kiniksa Pharmaceuticals International Plc (KNSA) Key Statistics

in dollars & INR

Previous Close
$18.88
Open
$18.96
Today's High
$19.19
Today's Low
$18.74
Market Capitalization
$1.4B
Today's Volume
$280.7K
52 Week High
$28.15
52 Week Low
$16.56
Revenue TTM
$384.1M
EBITDA
$-24.4M
Earnings Per Share (EPS)
$-0.12
Profit Margin
-2.36%
Quarterly Earnings Growth YOY
5.5%
Return On Equity TTM
-2.15%

How to invest in Kiniksa Pharmaceuticals International Plc Stock (KNSA) from India?

It is very easy for Indian residents to invest directly in Kiniksa Pharmaceuticals International Plc from India. Indian investors can open a free US stocks account on the INDmoney app. You can find live prices of the Kiniksa Pharmaceuticals International Plc stock in both Indian Rupees (INR) and US Dollars (USD). Search for Kiniksa Pharmaceuticals International Plc or KNSA on the INDmoney app and click on Buy or SIP. You can invest by choosing quantities of shares of Kiniksa Pharmaceuticals International Plc or rupee/ dollar value or set up a fixed SIP amount to be invested every month or week.

For example: You can easily buy Rs.100 worth of Kiniksa Pharmaceuticals International Plc shares which would translate to 0.046 fractional shares of Kiniksa Pharmaceuticals International Plc as of today. Learn more about fractional investing.

Indians can now also easily transfer and add money to their US stocks account via the INDmoney app. Invest in US Stocks from India, including recognised companies like Kiniksa Pharmaceuticals International Plc, in just a few clicks!

Returns in Kiniksa Pharmaceuticals International Plc (KNSA) for Indian investors in Rupees

The Kiniksa Pharmaceuticals International Plc stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

Investment Value

₹1,00,000

  • 1Y

  • 3Y

  • 5Y

  • 7Y

  • 10Y

Kiniksa Pharmaceuticals International Plc investment value today

Current value as on today

₹1,06,217

Returns

₹6,217

(+6.22%)

Returns from Kiniksa Pharmaceuticals International Plc Stock

₹1,352 (+1.35%)

Dollar Returns

₹4,865 (+4.86%)

Indian investors sentiment towards Kiniksa Pharmaceuticals International Plc (KNSA)

33%

Period: Jan 5, 2025 to Feb 4, 2025. Change in 30 Days versus previous period

Search interest for Kiniksa Pharmaceuticals International Plc Stock from India on INDmoney has increased by 33% in the last 30 days, reflecting an upward trend in search activity.

Global Institutional Holdings in Kiniksa Pharmaceuticals International Plc

  • BlackRock Inc

    5.29%

  • Vanguard Group Inc

    4.57%

  • Fairmount Funds Management LLC

    4.44%

  • BRAIDWELL LP

    4.01%

  • Baker Bros Advisors LP

    3.90%

  • Rubric Capital Management LP

    3.35%

Analyst Recommendation on Kiniksa Pharmaceuticals International Plc

Buy

    90%Buy

    9%Hold

    0%Sell

Based on 11 Wall street analysts offering stock ratings for Kiniksa Pharmaceuticals International Plc(by analysts ranked 0 to 5 stars)

Based on 11 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
10
10
10
Hold
1
1
1
Sell
0
0
0

Analyst Forecast on Kiniksa Pharmaceuticals International Plc Stock (KNSA)

What analysts predicted

Upside of 92.1%

Target:

$36.00

Current:

$18.74

Insights on Kiniksa Pharmaceuticals International Plc Stock (Ticker Symbol: KNSA)

  • Price Movement

    In the last 3 years, KNSA stock has moved up by 83.3%
  • Increasing Revenue

    Revenue is up for the last 3 quarters, 79.85M → 112.21M (in $), with an average increase of 14.8% per quarter
  • Decreasing Net Profit

    Netprofit is down for the last 2 quarters, -3.90M → -12.69M (in $), with an average decrease of 224.8% per quarter
  • KNSA vs ITCI (1 yr)

    In the last 1 year, Intra-cellular Therapies, Inc. has given 89.1% return, outperforming this stock by 86.4%
  • KNSA vs ITCI (3 yr)

    In the last 3 years, Intra-cellular Therapies, Inc. has given 161.1% return, outperforming this stock by 77.8%
  • Price to Sales

    ForKNSA every $1 of sales, investors are willing to pay $3.5, whereas for Intra-cellular Therapies, Inc., the investors are paying $20.9 for every $1 of sales.

Kiniksa Pharmaceuticals International Plc Technicals Summary

Sell

Neutral

Buy

Kiniksa Pharmaceuticals International Plc is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

Kiniksa Pharmaceuticals International Plc (KNSA) Vs Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Kiniksa Pharmaceuticals International Plc logo
-5.69%
-21.37%
2.11%
74.81%
13.46%
Intra-cellular Therapies, Inc. logo
55.53%
72.74%
81.47%
149.54%
495.46%
Haleon Plc Spon Ads logo
0.32%
-1.35%
13.13%
27.94%
27.94%
Zoetis Inc. logo
3.64%
-6.94%
-12.34%
-14.17%
23.79%
Neurocrine Biosciences Inc. logo
9.68%
4.14%
4.99%
85.26%
44.35%
Viatris Inc. logo
-7.62%
-2.82%
-7.15%
-27.65%
-32.44%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Kiniksa Pharmaceuticals International Plc logo
143.0
NA
NA
-0.21
-0.02
-0.03
NA
6.06
Intra-cellular Therapies, Inc. logo
NA
NA
0.0
-0.71
-0.1
-0.07
NA
10.8
Haleon Plc Spon Ads logo
28.7
28.7
1.68
0.36
0.07
0.04
0.02
1.82
Zoetis Inc. logo
32.18
32.18
2.66
5.89
0.47
0.15
0.01
11.59
Neurocrine Biosciences Inc. logo
40.03
40.03
0.35
6.59
0.16
0.12
NA
26.87
Viatris Inc. logo
224.4
NA
0.07
2.68
-0.04
0.02
0.04
16.58
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Kiniksa Pharmaceuticals International Plc logo
Buy
$1.4B
13.46%
143.0
-2.36%
Intra-cellular Therapies, Inc. logo
Buy
$13.5B
495.46%
NA
-14.07%
Haleon Plc Spon Ads logo
Buy
$42.8B
27.94%
28.7
10.75%
Zoetis Inc. logo
Buy
$77.1B
23.79%
32.18
26.55%
Neurocrine Biosciences Inc. logo
Buy
$15.2B
44.35%
40.03
17.21%
Viatris Inc. logo
Hold
$13.5B
-32.44%
224.4
-5.87%

About Kiniksa Pharmaceuticals International Plc

Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response. The company was formerly known as Kiniksa Pharmaceuticals, Ltd and changed its name tpKiniksa Pharmaceuticals International, plc in June 2024. The company was incorporated in 2015 and is based in London, the United Kingdom.
Organization
Kiniksa Pharmaceuticals International Plc
Employees
297
CEO
Mr. Sanj K. Patel
Industry
Health Technology

Management People of Kiniksa Pharmaceuticals International Plc

NameTitle
Mr. Sanj K. Patel
CEO & Chairman of the Board
Mr. Eben Tessari
Senior VP & COO
Dr. John F. Paolini FACC, M.D., Ph.D.
Senior VP & Chief Medical Officer
Mr. Mark Ragosa C.F.A.
Senior VP & CFO
Mr. Michael R. Megna CPA
Chief Accounting Officer & Group VP of Finance
Ms. Mei Jang
Senior Vice President of Technical Operations
Mr. Chad Morin
Senior VP & Chief Compliance Officer
Ms. Madelyn Demsky Zeylikman
SVP, General Counsel & Secretary
Mr. Carsten Boess M.B.A.
Executive Vice President of Corporate Affairs
Ms. Martina Struck Ph.D.
Senior Vice President of Regulatory Affairs

Important FAQs about investing in KNSA Stock from India :

What is Kiniksa Pharmaceuticals International Plc share price today?

Kiniksa Pharmaceuticals International Plc share price today stands at $18.74, Open: $18.96 ; Previous Close: $18.88 ; High: $19.19 ; Low: $18.74 ; 52 Week High: $28.15 ; 52 Week Low: $16.56.

The stock opens at $18.96, after a previous close of $18.88. The stock reached a daily high of $19.19 and a low of $18.74, with a 52-week high of $28.15 and a 52-week low of $16.56.

Can Indians buy Kiniksa Pharmaceuticals International Plc shares?

Yes, Indians can invest in the Kiniksa Pharmaceuticals International Plc (KNSA) from India.

With INDmoney, you can buy Kiniksa Pharmaceuticals International Plc at 0 brokerage. The step-by-step process is as follows:

  • Open your zero cost US Stocks account and zero balance IND linked savings a/c (this can be done in less than 3 minutes)
  • Transfer funds to your US Stocks account using your IND linked savings a/c (It takes 24 hours excluding Saturday and Sunday). With INDmoney, you get the best INR USD exchange rates.
  • Once funds are transferred successfully, you can buy Kiniksa Pharmaceuticals International Plc at zero transaction cost.

How can I buy Kiniksa Pharmaceuticals International Plc shares from India?

It is very easy to buy Kiniksa Pharmaceuticals International Plc from India. With INDmoney, you can open a US stocks account in less than 3 minutes. Transfer funds in 24 hours and buy stocks very easily - that too at 0 brokerage. All this is done at 0 account opening & management fee, 0 brokerages, and at the same time you get the best rupee-US dollar exchange rate.

Can Fractional shares of Kiniksa Pharmaceuticals International Plc (KNSA) be purchased?

Yes, you can buy fractional shares of Kiniksa Pharmaceuticals International Plc with INDmoney app.

What are the documents required to start investing in Kiniksa Pharmaceuticals International Plc stocks?

To start investing in Kiniksa Pharmaceuticals International Plc, You will need the following documents:

  • Proof of Identification (PAN, Aadhaar etc)
  • Proof of address (Aadhaar, Voter ID etc)

These documents are required as per RBI's guidelines to create your IND linked savings a/c so that you can execute for global fund transfer. The entire process is paperless and can be completed seamlessly.

What are today’s High and Low prices of Kiniksa Pharmaceuticals International Plc Stock (KNSA)?

Today’s highest price of Kiniksa Pharmaceuticals International Plc (KNSA) is $19.19.

Today’s lowest price of Kiniksa Pharmaceuticals International Plc (KNSA) is $18.74.

What is today's market capitalisation of Kiniksa Pharmaceuticals International Plc?

Today's market capitalisation of Kiniksa Pharmaceuticals International Plc KNSA is 1.4B

What is the 52 Week High and Low Range of Kiniksa Pharmaceuticals International Plc Stock (KNSA)?

  • 52 Week High

    $28.15

  • 52 Week Low

    $16.56

What are the historical returns of Kiniksa Pharmaceuticals International Plc (KNSA)?

  • 1 Month Returns

    -5.69%

  • 3 Months Returns

    -21.37%

  • 1 Year Returns

    2.11%

  • 5 Years Returns

    13.46%

Who is the Chief Executive Officer (CEO) of Kiniksa Pharmaceuticals International Plc ?

Mr. Sanj K. Patel is the current Chief Executive Officer (CEO) of Kiniksa Pharmaceuticals International Plc.